These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 22468718)
1. Relation of bosentan, iloprost, and sildenafil with growth factor levels in monocrotaline-induced pulmonary hypertension. Yigitaslan S; Sirmagul B Clin Exp Hypertens; 2012; 34(3):222-9. PubMed ID: 22468718 [TBL] [Abstract][Full Text] [Related]
2. Synergistic therapeutic effects of 2-methoxyestradiol with either sildenafil or bosentan on amelioration of monocrotaline-induced pulmonary hypertension and vascular remodeling. Tofovic SP; Jones TJ; Bilan VP; Jackson EK; Petrusevska G J Cardiovasc Pharmacol; 2010 Nov; 56(5):475-83. PubMed ID: 20881615 [TBL] [Abstract][Full Text] [Related]
3. Assessment of the endothelial functions in monocrotaline-induced pulmonary hypertension. Sirmagul B; Ilgin S; Atli O; Usanmaz SE; Demirel-Yilmaz E Clin Exp Hypertens; 2013; 35(3):220-7. PubMed ID: 22967272 [TBL] [Abstract][Full Text] [Related]
4. The extracellular signal-regulated kinase is involved in the effects of sildenafil on pulmonary vascular remodeling. Zeng Z; Li Y; Jiang Z; Wang C; Li B; Jiang W Cardiovasc Ther; 2010; 28(1):23-9. PubMed ID: 20074256 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension. Austin MJ; McDougall NI; Wendon JA; Sizer E; Knisely AS; Rela M; Wilson C; Callender ME; O'Grady JG; Heneghan MA Liver Transpl; 2008 Mar; 14(3):287-91. PubMed ID: 18306330 [TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension. Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478 [TBL] [Abstract][Full Text] [Related]
7. Treatment of severe pulmonary hypertension secondary to scleroderma: a three-drug approach. Catapano-Minotti G; Corsonello A; Guadalupi G; Spani R; Antonelli-Incalzi R Intern Med; 2008; 47(6):511-3. PubMed ID: 18344637 [TBL] [Abstract][Full Text] [Related]
8. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849 [TBL] [Abstract][Full Text] [Related]
9. Sildenafil improves long-term effect of endothelial progenitor cell-based treatment for monocrotaline-induced rat pulmonary arterial hypertension. Yen CH; Tsai TH; Leu S; Chen YL; Chang LT; Chai HT; Chung SY; Chua S; Tsai CY; Chang HW; Ko SF; Sun CK; Yip HK Cytotherapy; 2013 Feb; 15(2):209-23. PubMed ID: 23321332 [TBL] [Abstract][Full Text] [Related]
10. Therapy with sildenafil or bosentan decreases pulmonary vascular resistance in patients ineligible for heart transplantation because of severe pulmonary hypertension. Perez-Villa F; Farrero M; Sionis A; Castel A; Roig E J Heart Lung Transplant; 2010 Jul; 29(7):817-8. PubMed ID: 20363156 [No Abstract] [Full Text] [Related]
11. Oral sildenafil prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats. Liu H; Liu ZY; Guan Q Interact Cardiovasc Thorac Surg; 2007 Oct; 6(5):608-13. PubMed ID: 17670742 [TBL] [Abstract][Full Text] [Related]
12. Rosuvastatin, sildenafil and their combination in monocrotaline-induced pulmonary hypertension in rat. Jasińska-Stroschein M; Owczarek J; Wesołowska A; Orszulak-Michalak D Acta Pharm; 2014 Sep; 64(3):345-53. PubMed ID: 25296680 [TBL] [Abstract][Full Text] [Related]
13. Fluoxetine protects against monocrotaline-induced pulmonary arterial remodeling by inhibition of hypoxia-inducible factor-1α and vascular endothelial growth factor. Han DD; Wang Y; Zhang XH; Liu JR; Wang HL Can J Physiol Pharmacol; 2012 Apr; 90(4):445-54. PubMed ID: 22448962 [TBL] [Abstract][Full Text] [Related]
14. Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats. Clozel M; Hess P; Rey M; Iglarz M; Binkert C; Qiu C Exp Biol Med (Maywood); 2006 Jun; 231(6):967-73. PubMed ID: 16741032 [TBL] [Abstract][Full Text] [Related]
15. Sildenafil limits monocrotaline-induced pulmonary hypertension in rats through suppression of pulmonary vascular remodeling. Yen CH; Leu S; Lin YC; Kao YH; Chang LT; Chua S; Fu M; Wu CJ; Sun CK; Yip HK J Cardiovasc Pharmacol; 2010 Jun; 55(6):574-84. PubMed ID: 20224427 [TBL] [Abstract][Full Text] [Related]
16. [The treatment of idiopathic pulmonary artery hypertension and its relation to systemic scleroderma]. Humbert M Rev Med Interne; 2007 Dec; 28 Suppl 4():S273-6. PubMed ID: 17961866 [No Abstract] [Full Text] [Related]
17. Consecutive use of sildenafil and bosentan for the treatment of pulmonary arterial hypertension associated with collagen vascular disease: sildenafil as reliever and bosentan as controller. Kamata Y; Iwamoto M; Minota S Lupus; 2007; 16(11):901-3. PubMed ID: 17971364 [TBL] [Abstract][Full Text] [Related]
18. Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil. Mouchaers KT; Schalij I; de Boer MA; Postmus PE; van Hinsbergh VW; van Nieuw Amerongen GP; Vonk Noordegraaf A; van der Laarse WJ Eur Respir J; 2010 Oct; 36(4):800-7. PubMed ID: 20351034 [TBL] [Abstract][Full Text] [Related]
19. Effects of everolimus in combination with sildenafil in monocrotaline-induced pulmonary hypertension in rats. Ilgin S; Burukoglu D; Atli O; Sirmagul B Cardiovasc Toxicol; 2012 Mar; 12(1):46-55. PubMed ID: 21811847 [TBL] [Abstract][Full Text] [Related]